Media coverage about PhaseRx (NASDAQ:PZRX) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PhaseRx earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.9945695380549 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
PhaseRx (NASDAQ PZRX) opened at $1.00 on Monday. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of -12.03. PhaseRx has a 1 year low of $0.54 and a 1 year high of $1.95.
PhaseRx (NASDAQ:PZRX) last posted its earnings results on Thursday, November 9th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.14.
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
What are top analysts saying about PhaseRx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhaseRx Inc. and related companies.